---
title: "Barclays Reaffirms Their Buy Rating on Galderma Group AG (GALD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277427728.md"
description: "Barclays has reaffirmed a Buy rating on Galderma Group AG (GALD) with a price target of CHF195.00, as reported by James Gordon CFA. He focuses on the Healthcare sector and has an average return of 9.4% with a 54.55% success rate on his stock recommendations. Previously, Jefferies also maintained a Buy rating on Galderma with a price target of CHF190.00."
datetime: "2026-03-02T08:16:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277427728.md)
  - [en](https://longbridge.com/en/news/277427728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277427728.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277427728.md) | [繁體中文](https://longbridge.com/zh-HK/news/277427728.md)


# Barclays Reaffirms Their Buy Rating on Galderma Group AG (GALD)

In a report released today, James Gordon CFA from Barclays maintained a Buy rating on Galderma Group AG, with a price target of CHF195.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Galderma Group AG, and GlaxoSmithKline. According to TipRanks, Gordon CFA has an average return of 9.4% and a 54.55% success rate on recommended stocks.

In a report released on February 16, Jefferies also maintained a Buy rating on the stock with a CHF190.00 price target.

### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Samsung Biologics Acquires GSK's Manufacturing Facility in US](https://longbridge.com/en/news/281465578.md)
- [Britain agrees full text of US-UK pharmaceutical trade deal](https://longbridge.com/en/news/281553614.md)
- [Tritonpoint Wealth LLC Sells 10,771 Shares of Zoetis Inc. $ZTS](https://longbridge.com/en/news/281684930.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [FDA Approves Dosing Interval Extension Up To 20 Weeks For EYLEA HD In WAMD And DME](https://longbridge.com/en/news/281744271.md)